Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) EBITDA: 2018-2022

Historic EBITDA for ADC Therapeutics (ADCT) over the last 5 years, with Dec 2022 value amounting to -$123,627.

  • ADC Therapeutics' EBITDA fell 1060.85% to -$36.1 million in Q3 2023 from the same period last year, while for Sep 2023 it was -$127.4 million, marking a year-over-year decrease of 12.77%. This contributed to the annual value of -$123,627 for FY2022, which is 52.76% up from last year.
  • Per ADC Therapeutics' latest filing, its EBITDA stood at -$123,627 for FY2022, which was up 52.76% from -$261,720 recorded in FY2021.
  • Over the past 5 years, ADC Therapeutics' EBITDA peaked at -$119,399 during FY2019, and registered a low of -$261,720 during FY2021.
  • In the last 3 years, ADC Therapeutics' EBITDA had a median value of -$219,263 in 2020 and averaged -$201,537.
  • In the last 5 years, ADC Therapeutics' EBITDA crashed by 83.64% in 2020 and then surged by 52.76% in 2022.
  • Yearly analysis of 5 years shows ADC Therapeutics' EBITDA stood at -$125,941 in 2018, then increased by 5.19% to -$119,399 in 2019, then crashed by 83.64% to -$219,263 in 2020, then dropped by 19.36% to -$261,720 in 2021, then skyrocketed by 52.76% to -$123,627 in 2022.